The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Lifts full-year outlook as obesity drug boom accelerates
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility
The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
Subscribe To Our Newsletter & Stay Updated
